Novartis investors are placing increased pressure on Novartis’ dealmaking strategy after facing setbacks to drugs acquired ...

The health care industry has invested heavily in point solutions ($100 billion). We have one tool for scheduling, another for ...

The biopharmaceutical industry is undergoing a profound transformation, driven by the emergence of agentic artificial intelligence (AI). Unlike traditional AI models that require continuous human ...

This June, ten of the life sciences industry’s most respected board members came to New York for Accenture’s second annual Life Sciences Board Forum for something this industr ...

GLP-1 medications might be most well-known as weight-loss options, but they were originally developed as a treatment for type 2 diabetes. For many patients, the drugs remain a highly effective ...

Senior Lecturer in the Entrepreneurial Management Unit at Harvard Business School (HBS). In the MBA program, Satish has previously taught The Entrepreneurial Manager, a required first-year MBA course, ...

Governance pressure is intensifying at Novartis, with calls to penalize dealmakers for failed M&A and align executive pay ...

Artisan Partners' David Samra is publicly calling for Novartis to overhaul its board and compensation structure following ...

A patient checks in and sits down, closer to their own health than they will be at almost any other point in the year, turning over the questions they mean to ask, the decision they're about to make.

Learn how ClaimGuardRx addresses both diversion and fraud through a single, conversational platform. Understand why the voice ...

An oversubscribed $70 million Series B, co-led by Alpha Wave and YK Bioventures with Eli Lilly participation, funds clinical ...

Caspian Therapeutics was launched with $50 million to progress KO-7246 through IND-enabling development and early clinical evaluation in patients with diabetes. Menin inhibition is positioned as ...